Nine-month interim report (Q3) 2010

(unaudited)

Performance for the period
(Comparative figures for the same period of last year are shown in brackets /
sales growth is measured in local currencies) 

- Sales growth continued during Q3, during which vaccine sales rose by 10%
- Total revenue for the nine months was DKK 1,553 million (1,393) with 11%
growth in vaccine sales 
- Operating profit before depreciation and amortisation (EBITDA) for the nine
months was DKK 204 million (176) and increased by 16% 
- Operating profit (EBIT) for the nine months was DKK 132 million (117) and
increased by 13% 
- Profit for the nine months was DKK 88 million (82) and increased by 7%

During the first nine months of the year ALK experienced satisfactory growth in
sales and earnings. Growth was broadly based on products and markets, and the
acquisitions undertaken made a positive contribution to this development. 

In mid-October, the competent European authorities for medicinal products
approved ALK's new adrenaline pen, JEXT®, for the treatment of severe, acute
allergic reactions. ALK expects to launch JEXT® on the first European markets
in the months ahead. 

Expectations for 2010 unchanged
For the 2010 financial year, including the impact of acquisitions undertaken,
ALK still anticipates growth of 9-12% in sales of allergy vaccines, measured in
local currencies. Similarly, ALK still expects a gain of 10-15% in operating
profit (EBITDA and EBIT). 


Hørsholm, 16 November 2010

ALK-Abelló A/S


Contacts:
Jens Bager, President and CEO, tel. +45 4574 7576

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Press: Martin Barlebo, tel. +45 4574 7901, mobile +45 2064 1143

ALK holds a conference call for analysts and investors today at 3.30 p.m. (CET)
at which Jens Bager, President and CEO, and Flemming Pedersen, CFO, will
present the results. Participants in the conference call are kindly requested
to call in before 3.25 p.m. (CET). Danish participants should call in on tel.
+45 7014 0453 and international participants should call in on tel. +44 (0) 207
108 63 03. The conference call will also be webcast on our website:
www.alk-abello.com, where the related presentation will be available shortly
before the conference call begins.